Blood Pressure Drugs Reduce Mortality in Patients with Diabetes: The ADVANCE Study
Stephen MacMahon
Raymond Gibbons
REFERENCE: Abstract 312 Hot Line 1 Sunday, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
STEPHEN MACMAHON, The George Institute, University of Sydney
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MN
The randomised placebo controlled ADVANCE study of 11000 patients with diabetes has demonstrated that a combination of the ACE inhibitor, perindopril, with the diuretic indapamide can lower blood pressure and mortality. The investigators saw an impact even in patients who did not have high blood pressure. Lead study author Stephen MacMahon said this approach should be included in current practice guidelines. Sarah Maxwell spoke with him at the meeting in Vienna.
Raymond Gibbons commented on Stephen MacMahon’s presentation of the ADVANCE study.
STEPHEN MACMAHON, The George Institute, University of Sydney
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MN
The randomised placebo controlled ADVANCE study of 11000 patients with diabetes has demonstrated that a combination of the ACE inhibitor, perindopril, with the diuretic indapamide can lower blood pressure and mortality. The investigators saw an impact even in patients who did not have high blood pressure. Lead study author Stephen MacMahon said this approach should be included in current practice guidelines. Sarah Maxwell spoke with him at the meeting in Vienna.
Raymond Gibbons commented on Stephen MacMahon’s presentation of the ADVANCE study.
